semaglutide glp 1 Diabetes Patients Also Struggle to Access GLP-1 Agonists Semaglutide | GLP-1 Receptor Agonist

The trade-off between greater efficacy and increased side effect burden is real

Careful attention to evidence-based nutritional and behavior modification can help mitigate the adverse effects of these challenges

Metabolically healthy obesity

This is encouraging and has potential to be relevant when considering prescribing choices to lower ICP

This is a complex moment to navigate for food companies

They are indicated for type 2 diabetes management, weight reduction in obesity, and cardiovascular risk reduction, with ongoing investigation into metabolic dysfunction-associated steatohepatitis, chronic kidney disease, and heart failure with preserved ejection fraction